Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 408 of 5804
-
Triple attack: new cell therapy combo takes on melanoma
Disease control Recruiting nowThe purpose of this study is to assess the feasibility, safety and efficacy of combination immunotherapy based on CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines modified with GM-CSF and B7-2 (CD86) against melanoma, which targets CAR T specific surf…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 26, 2026 15:20 UTC
-
New hope for elderly leukemia patients: study tests gentler chemo combo
Disease control Recruiting nowThis study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid le…
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Timing is everything: new trial tests early vs. delayed surgery for spinal cord injury
Disease control Recruiting nowTo compare the outcome of early versus delayed surgical decompression among patients presenting with traumatic spinal cord injury in a tertiary care hospital.
Sponsor: Fauji Foundation Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to save bladders in HER2-positive cancer patients
Disease control Not yet recruitingThis study aims to evaluate the efficacy of disitamab vedotin combined with toripalimab as a bladder-preserving treatment combination in patients with HER2 positive locally advanced MIBC, including one year bladder-intact DFS (BI-DFS) and safety.
Phase: PHASE2 • Sponsor: Renmin Hospital of Wuhan University • Aim: Disease control
Last updated Jun 26, 2026 13:16 UTC
-
New cocktail of drugs targets Hard-to-Treat bile duct cancer
Disease control Not yet recruitingThis trial is a single-arm exploratory phase II clinical study initiated by the investigator. Subjects who met the research criteria were screened and enrolled to receive the treatment regimen of disitamab vedotin combined with lenvatinib and PD-1 inhibitor. During the treatment…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:45 UTC
-
Radiation and immunotherapy combo shows promise for tough colon cancers
Disease control Recruiting nowMost colorectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) subtypes, which show limited efficacy to PD-1 inhibitors. Radiotherapy can enhance the release of tumor-associated antigens, thereby improving the responsiveness of pMMR/MSS colorectal ca…
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New online tool aims to stop postpartum depression before it starts
Prevention ENROLLING_BY_INVITATIONThe goal of this randomized controlled study is to evaluate whether an online intervention that combines psychoeducation and affective cognitive training can help prevent postpartum depression in pregnant women and co-parents who have been identified as having risk factors for po…
Phase: NA • Sponsor: Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC
-
AI boosts breast cancer detection in ultrasound study
Diagnosis CompletedThis is a retrospective, fully-crossed, multi-reader, multi-case (MRMC) study to evaluate the effectiveness of 'CadAI-B Dx' (CadAI-B) for decision support in breast ultrasound. The study compares the diagnostic performance of readers interpreting breast ultrasound images with and…
Phase: NA • Sponsor: BeamWorks Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
New hope for duchenne: experimental drug ENTR-601-45 enters human trials
Disease control Recruiting nowThis is a study of the investigational medicine ENTR-601-45 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition. The researchers want to: Test how safe ENTR-601-45 is, learn about any side effects, and look at the potential positive effects of ENT…
Phase: PHASE1, PHASE2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug shows promise in lung cancer fight
Disease control Recruiting nowThis is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer. Eligible subjects will receive SKB518 monotherapy, until radiographic disease progress…
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for tough myeloma: drug plus radiation trial launches
Disease control Recruiting nowThis phase I/II trial tests the safety and effectiveness of extramedullary disease (EMD)-directed external beam radiation therapy (EBRT) in combination with talquetamab for the treatment of multiple myeloma patients with extramedullary disease. Extramedullary disease in multiple …
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 26, 2026 18:48 UTC
-
New combo therapy aims to stall rare gut tumors
Disease control Recruiting nowThere is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors. This trial is conducted to evaluate sirolimus for injection (a…
Phase: PHASE2, PHASE3 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy plus chemo and radiation: new hope for lung cancer?
Disease control Recruiting nowTo evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Phase: PHASE2 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to halt brain tumors in lung cancer patients
Disease control Recruiting nowThis study is a multicenter, randomized, prospective Phase III study to evaluate the efficacy and safety of anlotinib plus whole-brain radiotherapy (WBRT) compared with WBRT alone in small cell lung cancer (SCLC) patients with brain metastases. Additionally, by investigating the …
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for back pain: experimental drug LNK01001 enters final trial phase
Disease control Recruiting nowThe aim of this study is to evaluate the efficacy and safety of LNK01001 in subjects with active ankylosing spondylitis. The study is comprised of a 16-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 36-week open-label, long-…
Phase: PHASE3 • Sponsor: Lynk Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug shows promise for Tough-to-Treat stomach cancer
Disease control OngoingThe purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can an eye injection bring back light for the blind?
Disease control Recruiting nowThe goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection bilaterally every 6 weeks in patients with late-stage retinitis pigmentosa (RP). Late-stage RP patients will include those patie…
Phase: PHASE2 • Sponsor: Kiora Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New heart procedure could keep AFib away longer
Disease control Recruiting nowThis study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to pulmonary vein isolation (PVI) outperforms PVI alone using pulsed field ablation (PFA) in maintaining sinus rhythm for persistent atrial fibri…
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced bile duct cancer: liver transplant after targeted radiation
Disease control Recruiting nowThe study hypothesis is that liver transplantation after selective internal radiation therapy (SIRT) and chemotherapy would improve 3-year overall survival in patients with locally advanced (unresectable but non-metastatic) intrahepatic cholangiocarcinoma. It is planned to inclu…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
5-Day radiation for breast cancer: a game changer?
Disease control Recruiting nowThis clinical trial tests how well ultra-hypofractionated (UF) whole breast irradiation (WBI) with lumpectomy cavity boost (CB) works in treating patients with stage I-III breast cancer. Breast conservation therapy (BCT) is the recommended treatment for patients with early stage …
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC